The Trump administration has announced plans to terminate the subsidy for Medicare drug premiums, which has helped temper drug costs for seniors. Reports indicate that this decision could lead to a significant surge in drug costs for Medicare beneficiaries, as the subsidy program is set to be discontinued. Experts predict that Medicare Part D premiums may rise sharply as a result of this policy change. Stocks of companies like CNC, UNH, CVS, and HUM have already shown declines in after-hours trading following the news. The end of this program is likely to burden seniors with higher healthcare costs, raising concerns over affordability.